Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) from a hold rating to a buy rating in a report published on Tuesday. They currently have $4.25 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Separately, Wedbush reissued a neutral rating and issued a $4.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, June 20th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of Hold and an average price target of $9.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 3.51 on Tuesday. The stock’s 50 day moving average price is $3.78 and its 200 day moving average price is $4.26. The firm’s market capitalization is $128.81 million. Tetraphase Pharmaceuticals has a one year low of $3.12 and a one year high of $12.45.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.01. Tetraphase Pharmaceuticals had a negative net margin of 821.25% and a negative return on equity of 35.43%. The company earned $1.20 million during the quarter, compared to analyst estimates of $2.05 million. During the same period in the previous year, the company posted ($0.72) EPS. The company’s quarterly revenue was down 63.6% compared to the same quarter last year. Analysts expect that Tetraphase Pharmaceuticals will post ($1.98) EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG purchased a new stake in Tetraphase Pharmaceuticals during the first quarter valued at $102,000. Teton Advisors Inc. purchased a new stake in Tetraphase Pharmaceuticals during the second quarter valued at $103,000. Parametric Portfolio Associates LLC purchased a new stake in Tetraphase Pharmaceuticals during the second quarter valued at $128,000. ProShare Advisors LLC boosted its stake in Tetraphase Pharmaceuticals by 1.2% in the second quarter. ProShare Advisors LLC now owns 31,696 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 383 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Tetraphase Pharmaceuticals by 2,618.8% in the second quarter. Nisa Investment Advisors LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $187,000 after buying an additional 41,900 shares during the last quarter. 59.41% of the stock is owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.